Novartis bond sales come six months after Pfizer offered $1.25 billion worth of 10-year bonds connected to gain access to and sustainability enhancements.
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
The drugmaker said in a Sept. 16 press release that its goal is to broaden the number of patients who receive its drugs by a minimum of 200 percent by 2025. It also aims to enhance an initiative to reach patients with leprosy, malaria, sickle cell illness and Chagas illness, with the objective of reaching 23 million patients by 2025.
Katie Adams –
Wednesday, September 23rd, 2020
More short articles on drug store: FDA to reveal more stringent rules on emergency usage permission for COVID-19 vaccineOptumRxs 3 recently approved drugs to watchJ&& J single-dose COVID-19 vaccine ends up being 4th US candidate to get in late-stage testing.
Swiss pharma giant Novartis just recently amassed about $2.1 billion from investors by offering bonds connected to its promises to make its treatments more accessible in lower-income nations, according to STAT.
Must Novartis fail to achieve its gain access to and sustainability goals, financiers will get greater interest payments. The drugmaker plans to release yearly progress reports on its efforts.